Immunohistochemical analysis of tumor samples further documented that in comparison with single regimens, the combined BRAFi and imatinib treatment dramatically reduced cell proliferation and led to apoptotic tumor cell death, as shown by the in situ expression of cleaved caspase‐3 and decreased Ki67 (Fig 6D). This evidence concerns the gene MKI67 and neoplasm.